About Bridge-like lipid transfer protein family member 2
Bridge-like lipid transfer protein family member 2 (BLTP2) is a protein
from Homo sapiens identified by UniProt accession
Q14667, 2235 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Bridge-like lipid transfer protein family member 2 |
|---|
| UniProt accession | Q14667 |
|---|
| Gene | BLTP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2235 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (69)
Diseases linked to this target (Open Targets).
- systolic blood pressure · score 0.12
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- prostate cancer · score 0.11
- cancer · score 0.07
- urate measurement · score 0.07
- neoplasm · score 0.06
- reticulocyte count · score 0.06
- platelet count · score 0.06
- insomnia measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14667-F1 | alphafold | PREDICTED | 70.79 | — |
Amino-acid sequence (2235 residues)
MPLFFSALLV LLLVALSALF LGRWLVVRLA TKWCQRKLQA ELKIGSFRFF WIQNVSLKFQ QHQQTVEIDN LWISSKLLSH DLPHYVALCF GEVRIRTDLQ KVSDLSAPFS QSAGVDQKEL SFSPSLLKIF CQLFSIHVDA INIMVLKVDT SESLWHIQIS RSRFLLDSDG KRLICEVSLC KINSKVLKSG QLEDTCLVEL SLALDLCLKV GISSRHLTAI TVDVWTLHAE LHEGLFQSQL LCQGPSLASK PVPCSEVTEN LVEPTLPGLF LLQQLPDQVK VKMENTSVVL SMNSQKRHLT WTLKLLQFLY HRDEDQLPLR SFTANSDMAQ MSTELLLEDG LLLSQSRQRI VCLNSLKASV QVTTIDLSAS LVLNTCIIHY RHQEFSHWLH LLALETQGSS SPVLKQRKKR TFPQILAPII FSTSISNVNI SIQLGDTPPF ALGFNSISLD YQHLRPQSIH QRGVLTVDHL CWRVGSDSHI QRAPHPPNMH VWGEALVLDS FTLQGSYNQP LGLSSTQSDT LFLDCTIRGL QVEASDTCAQ CLSRILSLMG PQSGKSAVSR HSSFGESVSL LWKVDLKVED MNLFTLSALV GASEVRLDTL TILGSAETST VGIQGLVLAL VKSVTEKMQP CCKAPDIPTP VLSLSMLSIT YHSSIRSLEV QCGAGLTLLW SPPDHMYLYQ HVLATLQCRD LLRATVFPET VPSLALETSG TTSELEGRAP EPLPPKRLLN LTLEVSTAKL TAFVAEDKFI TLAAESVSLS RHGGSLQAYC PELAAGFDGN SIFNFKEVEV QLLPELEEMI LHRNPFPALQ TLRNRVWLLS FGSVSVEFPY QYDFSRTLDE AVGVQKWLKG LHQGTRAWAS PSPVPLPPDL LLKVEHFSWV FLDDVFEVKL HDNYELMKDE SKESAKRLQL LDAKVAALRK QHGELLPARK IEELYASLER KNIEIYIQRS RRLYGNTPMR RALLTWSLAG LELVALADAS FHGPEHVVEQ VQELDPGSPF PPEGLDLVIQ WCRMLKCNVK SFLVRIRDYP RYLFEIRDWR LMGRLVGTEQ SGQPCSRRRQ ILHLGLPWGN VAVERNMPPL KFYHDFHSEI FQYTVVWGPC WDPAWTLIGQ CVDLLTKPSA DPSPPLPWWD KSRLLFHGDW HMDIEQANLH QLATEDPYNT TENMHWEWSH LSFHWKPGQF VFKGDLDINV RTASKYDDCC FLHLPDLCMT LDLQWLCHGN PHDHHSVTLR APEFLPEVPL GQLHDSYRAF RSENLNLSIK MDLTRHSGTI SQPRILLYSS TLRWMQNFWA TWTSVTRPIC RGKLFNNLKP SKKKLGQHYK QLSYTALFPQ LQVHYWASFA QQRGIQIECS QGHVFTRGTQ RLIPQAGTVM RRLISDWSVT QMVSDLSQVT VHLMASPTEE NADHCLDPLV TKTHLLSLSS LTYQRHSNRT AEEELSARDG DPTFHTHQLH LVDLRISWTT TNRDIAFGLY DGYKKAAVLK RNLSTEALKG LKIDPQMPAK KPKRGVPTSA SAPPRVNTPS FSGQPDKGSS GGAYMLQKLI EETDRFVVFT EEESGMSDQL CGIAACQTDD IYNRNCLIEL VNCQMVLRGA ETEGCVIVSA AKAQLLQCQH HPAWYGDTLK QKTSWTCLLD GMQYFATTES SPTEQDGRQL WLEVKNIEEH RQRSLDSVQE LMESGQAVGG MVTTTTDWNQ PAEAQQAQQV QRIISRCNCR MYYISYSHDI DPELATQIKP PEVLENQEKE DLLKKQEGAV DTFTLIHHEL EISTNPAQYA MILDIVNNLL LHVEPKRKEH SEKKQRVRFQ LEISSNPEEQ RSSILHLQEA VRQHVAQIRQ LEKQMYSIMK SLQDDSKNEN LLDLNQKLQL QLNQEKANLQ LESEELNILI RCFKDFQLQR ANKMELRKQQ EDVSVVRRTE FYFAQARWRL TEEDGQLGIA ELELQRFLYS KVNKSDDTAE HLLELGWFTM NNLLPNAVYK VVLRPQSSCQ SGRQLALRLF SKVRPPVGGI SVKEHFEVNV VPLTIQLTHQ FFHRMMGFFF PGRSVEDDEV GDEEDKSKLV TTGIPVVKPR QLIATDDAVP LGPGKGVAQG LTRSSGVRRS FRKSPEHPVD DIDKMKERAA MNNSFIYIKI PQVPLCVSYK GEKNSVDWGD LNLVLPCLEY HNNTWTWLDF AMAVKRDSRK ALVAQVIKEK LRLKSATGSE VRGKLETKSD LNMQQQEEEE KARLLIGLSV GDKNPGKKSI FGRRK
Explore Bridge-like lipid transfer protein family member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets